"Adalimumab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A humanized monoclonal antibody that binds specifically to TNF-ALPHA and blocks its interaction with endogenous TNF RECEPTORS to modulate INFLAMMATION. It is used in the treatment of RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS; CROHN'S DISEASE and ULCERATIVE COLITIS.
| Descriptor ID |
D000068879
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.060.250 D12.776.124.790.651.114.224.060.250 D12.776.377.715.548.114.224.200.250
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Adalimumab".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Adalimumab [D12.776.124.486.485.114.224.060.250]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Adalimumab [D12.776.124.790.651.114.224.060.250]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
- Adalimumab [D12.776.377.715.548.114.224.200.250]
Below are MeSH descriptors whose meaning is more specific than "Adalimumab".
This graph shows the total number of publications written about "Adalimumab" by people in this website by year, and whether "Adalimumab" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 2 | 2 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 3 | 3 |
| 2009 | 0 | 3 | 3 |
| 2010 | 0 | 3 | 3 |
| 2011 | 0 | 2 | 2 |
| 2013 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2017 | 0 | 4 | 4 |
| 2021 | 0 | 2 | 2 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Adalimumab" by people in Profiles.
-
Thalidomide as an Effective Treatment in Sideroblastic Anemia, Immunodeficiency, Periodic Fevers, and Developmental Delay (SIFD). J Clin Immunol. 2023 05; 43(4):780-793.
-
Infliximab Can Be Effective in Pediatric Patients with Ulcerative Colitis and Primary Failure of Adalimumab. Ann Clin Lab Sci. 2022 Sep; 52(5):796-801.
-
Utilization of Antitumor Necrosis Factor Biologics in Very Early Onset Inflammatory Bowel Disease: A Multicenter Retrospective Cohort Study From North America. J Pediatr Gastroenterol Nutr. 2022 07 01; 75(1):64-69.
-
Pituitary Sarcoidosis in a Pediatric Patient Successfully Treated With Adalimumab and Methotrexate. J Investig Med High Impact Case Rep. 2021 Jan-Dec; 9:23247096211012191.
-
Cost-utility analysis of treatment options after initial tumor necrosis factor inhibitor therapy discontinuation in patients with rheumatoid arthritis. J Manag Care Spec Pharm. 2021 01; 27(1):73-83.
-
Influence of age at diagnosis on the clinical characteristics of Crohn's disease in Korea: Results from the CONNECT study. J Gastroenterol Hepatol. 2017 Oct; 32(10):1716-1722.
-
Comparative Effectiveness of Tumor Necrosis Factor Agents and Disease-modifying Antirheumatic Therapy in Children with Enthesitis-related Arthritis: The First Year after Diagnosis. J Rheumatol. 2018 01; 45(1):107-114.
-
Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis. Cochrane Database Syst Rev. 2017 05 08; 5:CD012657.
-
Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study. Lancet. 2017 04 29; 389(10080):1710-1718.
-
Tuberculosis Screening and Reactivation Among a National Cohort of Patients with Inflammatory Bowel Disease Treated with Tumor Necrosis Factor Alpha Antagonists. Inflamm Bowel Dis. 2017 02; 23(2):254-260.